Critical Path Institute® today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable development of advanced therapies for highly individualized conditions. Rapid advances in technologies such as antisense oligonucleotides, genome editing, gene therapies, and RNA-based treatments are making it possible to design precisely targeted interventions for very small patient populations, even individual patients. However, existing regulatory and reimbursement frameworks, built for population-based medicines and linear development models, are not equipped to keep pace, creating a growing gap that delays patient access.

Anopheles darlingi mosquitoes—a major vector of malaria in South America—are evolving in response to insecticides, which may make them harder to kill and malaria more difficult to control, according to a new study led by Harvard T.H. Chan School of Public Health. It is the first study to sequence a large number (>1000) of complete genomes of Anopheles mosquitoes in the Americas, where there are more than 600,000 cases of malaria annually, mostly in Brazil, Colombia, and Venezuela.